DPX-RSV, a Vaccine to Address an Unmet Medical Need
Another Approach to Prophylactic Vaccines
DPX-RSV or DPX-RSV(A) is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The DPX platform is formulated with the SHe peptide of group A RSV. The small hydrophobic glycoprotein (SH) of RSV is a type II transmembrane protein that forms pentameric transmembrane pores in infected cells. It functions as a viral ion channel and might impact viral fusion.1
RSV is the leading cause of early childhood bronchiolitis and pneumonia worldwide and results in significant hospitalizations in infants, the elderly, and immunocompromised individuals. To date, no prophylactic RSV vaccine has been approved for clinical use and there is an increasing recognition of the unmet medical need for an effective RSV vaccine for older persons.2
1 Gan SW, J Biol Chem, 2012
2 Falsey AR et al. Med Mal Infect. 2005